2021
DOI: 10.1038/s12276-021-00623-w
|View full text |Cite
|
Sign up to set email alerts
|

RBM24 exacerbates bladder cancer progression by forming a Runx1t1/TCF4/miR-625-5p feedback loop

Abstract: RNA–binding motif protein 24 (RBM24) acts as a multifunctional determinant of cell fate, proliferation, apoptosis, and differentiation during development by regulating premRNA splicing and mRNA stability. It is also implicated in carcinogenesis, but the functions of RBM24 in bladder cancer (BC) remain unclear. In the present study, we revealed that RBM24 was upregulated in BC tissues. Importantly, we found that a higher level of RBM24 was correlated with poor prognosis in BC patients. Overexpression of RBM24 p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
27
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 17 publications
(30 citation statements)
references
References 35 publications
(47 reference statements)
1
27
0
Order By: Relevance
“…Then, we used the following formula to calculate the tumor volume: tumor volume = (length × width 2)/2. After 28 days, the mice were euthanized by carbon dioxide asphyxiation [ 23 , 25 , 27 ]. The euthanasia protocol is as described previously [ 28 ].…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Then, we used the following formula to calculate the tumor volume: tumor volume = (length × width 2)/2. After 28 days, the mice were euthanized by carbon dioxide asphyxiation [ 23 , 25 , 27 ]. The euthanasia protocol is as described previously [ 28 ].…”
Section: Methodsmentioning
confidence: 99%
“…Morphometry and histology were detected by hematoxylin and eosin staining as described before [ 27 , 29 ]. BC and corresponding normal tissues were fixed in formalin solution and then embedded in conventional paraffin.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…In malignant pleural mesothelioma (MPM) (34,35) and thyroid cancer (TC) (36,37), miR-625 was found to be upregulated. It is downregulated in bladder cancer (38), nasopharyngeal carcinoma (NPC) (39), lung cancer (40)(41)(42)(43)(44)(45)(46), HCC (47), cervical cancer (CC) (48,49), osteosarcoma (50), melanoma (51)(52)(53)(54), laryngeal squamous cell carcinoma (LSCC) (55), acute myeloid leukemia (AML) (56), BC (57)(58)(59), glioma (60,61), esophageal cancer (EC) (62)(63)(64), clear cell renal cell carcinoma (65), GC (66)(67)(68)(69)(70), and pancreatic ductal adenocarcinoma (PDAC) (71). In colorectal cancer (CRC), the expression of miR-625 seems to vary, being either high or low.…”
Section: Mir-625 In Cancers Aberrant Expression Of Mir-625 In Cancersmentioning
confidence: 99%
“…In bladder cancer (38), NPC (39), HCC (47), osteosarcoma (50), LSCC (55), ccRCC (65), and PDAC ( 71), miR-625 plays a protective role. Up-regulation of miR-625 can affect tumor progression through different mechanisms of action.…”
Section: Other Cancersmentioning
confidence: 99%